F3 and neoplasm: Our prototype CAR T cell micropharmacy employs an antivascular tumor targeting strategy based on induction of selective tumor vessel infarction by CD13-targeted truncated tissue factor (TF), a key initiator of the extrinsic coagulation cascade [5].